Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 16;73(4):730-739.
doi: 10.1093/cid/ciab141.

Antibacterial Resistance Leadership Group 2.0: Back to Business

Henry F Chambers  1 , Scott R Evans  2 , Robin Patel  3 , Heather R Cross  4 , Anthony D Harris  5 , Yohei Doi  6   7 , Helen W Boucher  8 , David van Duin  9 , Ephraim L Tsalik  10   11 , Thomas L Holland  4   11 , Melinda M Pettigrew  12 , Pranita D Tamma  13 , Kathryn R Hodges  4 , Maria Souli  4 , Vance G Fowler  4   11
Affiliations

Antibacterial Resistance Leadership Group 2.0: Back to Business

Henry F Chambers et al. Clin Infect Dis. .

Abstract

In December 2019, the Antibacterial Resistance Leadership Group (ARLG) was awarded funding for another 7-year cycle to support a clinical research network on antibacterial resistance. ARLG 2.0 has 3 overarching research priorities: infections caused by antibiotic-resistant (AR) gram-negative bacteria, infections caused by AR gram-positive bacteria, and diagnostic tests to optimize use of antibiotics. To support the next generation of AR researchers, the ARLG offers 3 mentoring opportunities: the ARLG Fellowship, Early Stage Investigator seed grants, and the Trialists in Training Program. The purpose of this article is to update the scientific community on the progress made in the original funding period and to encourage submission of clinical research that addresses 1 or more of the research priority areas of ARLG 2.0.

Keywords: Antibacterial Resistance Leadership Group; clinical research; mentoring.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
ARLG 2.0: back to business. Abbreviations: ARLG, Antibacterial Resistance Leadership Group; FDA, US Food and Drug Administration.
Figure 2.
Figure 2.
Organization of ARLG. Abbreviations: ARLG, Antibacterial Resistance Leadership Group; PI, primary investigator; U, university; UCLA, University of California–Los Angeles; UCSF, University of California–San Francisco; UNC, University of North Carolina.
See this image and copyright information in PMC

References

    1. Chambers HF, Bartlett JG, Bonomo RA, et al. . Antibacterial Resistance Leadership Group: open for business. Clin Infect Dis 2014; 58:1571–6. - PMC - PubMed
    1. Lodise TP, Rosenkranz SL, Finnemeyer M, et al. . The emperor’s new clothes: prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with methicillin-resistant Staphylococcus aureus bloodstream infections (PROVIDE). Clin Infect Dis 2020; 70:1536–45. - PMC - PubMed
    1. Rybak MJ, Le J, Lodise TP, et al. . Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020; 77:835–64. - PubMed
    1. Tacconelli E, Carrara E, Savoldi A, et al. ; World Health Organization Pathogens Priority List Working Group . Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018; 18:318–27. - PubMed
    1. Henderson H, Luterbach CL, Cober E, et al. . The Pitt bacteremia score predicts mortality in nonbacteremic infections. Clin Infect Dis 2020; 70:1826–33. - PMC - PubMed

Publication types

MeSH terms

Substances